296 related articles for article (PubMed ID: 28104689)
1. Identification of apilimod as a first-in-class PIKfyve kinase inhibitor for treatment of B-cell non-Hodgkin lymphoma.
Gayle S; Landrette S; Beeharry N; Conrad C; Hernandez M; Beckett P; Ferguson SM; Mandelkern T; Zheng M; Xu T; Rothberg J; Lichenstein H
Blood; 2017 Mar; 129(13):1768-1778. PubMed ID: 28104689
[TBL] [Abstract][Full Text] [Related]
2. B-cell non-Hodgkin lymphoma: Selective vulnerability to PIKFYVE inhibition.
Gayle S; Landrette S; Beeharry N; Conrad C; Hernandez M; Beckett P; Ferguson SM; Xu T; Rothberg J; Lichenstein H
Autophagy; 2017 Jun; 13(6):1082-1083. PubMed ID: 28350209
[TBL] [Abstract][Full Text] [Related]
3. Snx10 and PIKfyve are required for lysosome formation in osteoclasts.
Sultana F; Morse LR; Picotto G; Liu W; Jha PK; Odgren PR; Battaglino RA
J Cell Biochem; 2020 Apr; 121(4):2927-2937. PubMed ID: 31692073
[TBL] [Abstract][Full Text] [Related]
4. Apilimod, a candidate anticancer therapeutic, arrests not only PtdIns(3,5)P2 but also PtdIns5P synthesis by PIKfyve and induces bafilomycin A1-reversible aberrant endomembrane dilation.
Sbrissa D; Naisan G; Ikonomov OC; Shisheva A
PLoS One; 2018; 13(9):e0204532. PubMed ID: 30240452
[TBL] [Abstract][Full Text] [Related]
5. The phosphatidylinositol-3-phosphate 5-kinase inhibitor apilimod blocks filoviral entry and infection.
Nelson EA; Dyall J; Hoenen T; Barnes AB; Zhou H; Liang JY; Michelotti J; Dewey WH; DeWald LE; Bennett RS; Morris PJ; Guha R; Klumpp-Thomas C; McKnight C; Chen YC; Xu X; Wang A; Hughes E; Martin S; Thomas C; Jahrling PB; Hensley LE; Olinger GG; White JM
PLoS Negl Trop Dis; 2017 Apr; 11(4):e0005540. PubMed ID: 28403145
[TBL] [Abstract][Full Text] [Related]
6. Apilimod alters TGFβ signaling pathway and prevents cardiac fibrotic remodeling.
Cinato M; Guitou L; Saidi A; Timotin A; Sperazza E; Duparc T; Zolov SN; Giridharan SSP; Weisman LS; Martinez LO; Roncalli J; Kunduzova O; Tronchere H; Boal F
Theranostics; 2021; 11(13):6491-6506. PubMed ID: 33995670
[No Abstract] [Full Text] [Related]
7. The PIKfyve Inhibitor Apilimod: A Double-Edged Sword against COVID-19.
Baranov MV; Bianchi F; van den Bogaart G
Cells; 2020 Dec; 10(1):. PubMed ID: 33375410
[TBL] [Abstract][Full Text] [Related]
8. PIKfyve inhibition increases exosome release and induces secretory autophagy.
Hessvik NP; Øverbye A; Brech A; Torgersen ML; Jakobsen IS; Sandvig K; Llorente A
Cell Mol Life Sci; 2016 Dec; 73(24):4717-4737. PubMed ID: 27438886
[TBL] [Abstract][Full Text] [Related]
9. PIKfyve, a class III PI kinase, is the target of the small molecular IL-12/IL-23 inhibitor apilimod and a player in Toll-like receptor signaling.
Cai X; Xu Y; Cheung AK; Tomlinson RC; Alcázar-Román A; Murphy L; Billich A; Zhang B; Feng Y; Klumpp M; Rondeau JM; Fazal AN; Wilson CJ; Myer V; Joberty G; Bouwmeester T; Labow MA; Finan PM; Porter JA; Ploegh HL; Baird D; De Camilli P; Tallarico JA; Huang Q
Chem Biol; 2013 Jul; 20(7):912-21. PubMed ID: 23890009
[TBL] [Abstract][Full Text] [Related]
10. Unexpected inhibition of the lipid kinase PIKfyve reveals an epistatic role for p38 MAPKs in endolysosomal fission and volume control.
Wible DJ; Parikh Z; Cho EJ; Chen MD; Jeter CR; Mukhopadhyay S; Dalby KN; Varadarajan S; Bratton SB
Cell Death Dis; 2024 Jan; 15(1):80. PubMed ID: 38253602
[TBL] [Abstract][Full Text] [Related]
11. Identification of PIKfyve kinase as a target in multiple myeloma.
de Campos CB; Zhu YX; Sepetov N; Romanov S; Bruins LA; Shi CX; Stein CK; Petit JL; Polito AN; Sharik ME; Meermeier EW; Ahmann GJ; Armenta IDL; Kruse J; Bergsagel PL; Chesi M; Meurice N; Braggio E; Stewart AK
Haematologica; 2020 Jun; 105(6):1641-1649. PubMed ID: 31582538
[TBL] [Abstract][Full Text] [Related]
12. Drug evaluation: apilimod, an oral IL-12/IL-23 inhibitor for the treatment of autoimmune diseases and common variable immunodeficiency.
Billich A
IDrugs; 2007 Jan; 10(1):53-9. PubMed ID: 17187316
[TBL] [Abstract][Full Text] [Related]
13. The Lipid Kinase PIKfyve Coordinates the Neutrophil Immune Response through the Activation of the Rac GTPase.
Dayam RM; Sun CX; Choy CH; Mancuso G; Glogauer M; Botelho RJ
J Immunol; 2017 Sep; 199(6):2096-2105. PubMed ID: 28779020
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of PIKfyve kinase prevents infection by Zaire ebolavirus and SARS-CoV-2.
Kang YL; Chou YY; Rothlauf PW; Liu Z; Soh TK; Cureton D; Case JB; Chen RE; Diamond MS; Whelan SPJ; Kirchhausen T
Proc Natl Acad Sci U S A; 2020 Aug; 117(34):20803-20813. PubMed ID: 32764148
[TBL] [Abstract][Full Text] [Related]
15. Brief report: a phase IIa, randomized, double-blind, placebo-controlled trial of apilimod mesylate, an interleukin-12/interleukin-23 inhibitor, in patients with rheumatoid arthritis.
Krausz S; Boumans MJ; Gerlag DM; Lufkin J; van Kuijk AW; Bakker A; de Boer M; Lodde BM; Reedquist KA; Jacobson EW; O'Meara M; Tak PP
Arthritis Rheum; 2012 Jun; 64(6):1750-5. PubMed ID: 22170479
[TBL] [Abstract][Full Text] [Related]
16. A family of PIKFYVE inhibitors with therapeutic potential against autophagy-dependent cancer cells disrupt multiple events in lysosome homeostasis.
Sharma G; Guardia CM; Roy A; Vassilev A; Saric A; Griner LN; Marugan J; Ferrer M; Bonifacino JS; DePamphilis ML
Autophagy; 2019 Oct; 15(10):1694-1718. PubMed ID: 30806145
[TBL] [Abstract][Full Text] [Related]
17. Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohn's disease.
Sands BE; Jacobson EW; Sylwestrowicz T; Younes Z; Dryden G; Fedorak R; Greenbloom S
Inflamm Bowel Dis; 2010 Jul; 16(7):1209-18. PubMed ID: 19918967
[TBL] [Abstract][Full Text] [Related]
18. Dual Inhibition of Bruton's Tyrosine Kinase and Phosphoinositide-3-Kinase p110
Alfaro J; Pérez de Arce F; Belmar S; Fuentealba G; Avila P; Ureta G; Flores C; Acuña C; Delgado L; Gaete D; Pujala B; Barde A; Nayak AK; Upendra TVR; Patel D; Chauhan S; Sharma VK; Kanno S; Almirez RG; Hung DT; Chakravarty S; Rai R; Bernales S; Quinn KP; Pham SM; McCullagh E
J Pharmacol Exp Ther; 2017 May; 361(2):312-321. PubMed ID: 28298527
[TBL] [Abstract][Full Text] [Related]
19. Activity of the novel BCR kinase inhibitor IQS019 in preclinical models of B-cell non-Hodgkin lymphoma.
Balsas P; Esteve-Arenys A; Roldán J; Jiménez L; Rodríguez V; Valero JG; Chamorro-Jorganes A; de la Bellacasa RP; Teixidó J; Matas-Céspedes A; Moros A; Martínez A; Campo E; Sáez-Borderías A; Borrell JI; Pérez-Galán P; Colomer D; Roué G
J Hematol Oncol; 2017 Mar; 10(1):80. PubMed ID: 28359287
[TBL] [Abstract][Full Text] [Related]
20. Vacuolin-1 inhibits autophagy by impairing lysosomal maturation via PIKfyve inhibition.
Sano O; Kazetani K; Funata M; Fukuda Y; Matsui J; Iwata H
FEBS Lett; 2016 Jun; 590(11):1576-85. PubMed ID: 27135648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
